NovaGo Therapeutics raised CHF 24 million to advance its lead program into a randomized proof-of-concept study for acute spinal cord injury.
- Amount
- $29.5M
- Stage
- Series B
- Announced
- 2 September 2026
- Leads
- Neurimmune, Pureos
- Other investors
- Swiss Paraplegic Foundation, Wings for Life
- Use of funds
- Advance the lead program into a proof-of-concept study in patients with acute spinal cord injury.
- Checked
- Announced by the company